Patent term can be extended only if it has not been able to be worked for the certain duration due to Patent term extension (hereinafter 'PTE') is restraints of significant for the patentee as well as the 3rd party who wants to work the patented inven...
Patent term can be extended only if it has not been able to be worked for the certain duration due to Patent term extension (hereinafter 'PTE') is restraints of significant for the patentee as well as the 3rd party who wants to work the patented invention.
However law of PTE has been amended many times and relevant rearch regarding PTE administrative plan has not been done sufficiently since the introduction in 1987.
The purpose of this study is not only the presentation of PTE impact on the medical and agricultural chemical industries but also the proposal of protecting said industries as the bio-technology develops in these days.
It is necessary, as a first step, to get the information about PTE such as purport, the background of introduction, origin, processes of application and examination. Then the PTE legislation backgrounds of U.S.A., Europe and Japan are examined with precedents to know how other countries manage PTE system. In the next step, the investigation is done for the Korean PTE system such as the status of examination handling, the precedent of judgement and the regulations related with the background of introduction, infringement of patent right, the constraint of validity, experimental use, etc.
In the following section, Korean PTE is considered in the aspect of impact on the medical and agricultural chemical industries, international harmony and influence on the barrier of international trade, proposing the prospect of related industries and protecting plan.
Finally, this study elucidates that it is of necessity to aid the industrial development balancing between public and private interest without the restrictions of protecting patentee's right in explaining article 96 of the Patent Act for the test helping the advancement of technology.
It is problematic to introduce the regulation that the clinical examination of late medicine manufacturer is not committed into the infringement of patent right during the patent term, since it is controversial in America. Therefore it has to be carefully considered owing to the possibility of conflict with TRIPs.